COMMUNIQUÉS West-GlobeNewswire

US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
29/11/2018
Invivoscribe also Receives National Reimbursement for CDx Assay in Japan SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and [...]
Virginia Spine Institute Expands World-Class Surgical Team With Hiring of Spine Surgeon Ehsan Jazini, MD
29/11/2018
Spine Surgeon Ehsan Jazini, MD, formerly of MedStar Health, joins Virginia Spine Institute to support growth of national spinal practice RESTON, Va., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Virginia Spine Institute welcomes [...]
iKang Healthcare Group, Inc. Extends Shareholder Rights Plan
29/11/2018
BEIJING, Nov. 29, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), announced today that its board of directors (the “Board of Directors”) has unanimously approved the [...]
Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors
29/11/2018
LONDON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s [...]
LIDDS Delårsrapport juli - september 2018
29/11/2018
JULI - SEPTEMBER 2018 Nettoomsättningen uppgick till 7,8 (0,2) KSEK Kostnaderna uppgick till 2,5 (1,5) MSEK Resultatet före och efter skatt uppgick till 5,4 (-1,5) MSEK Resultat per aktie uppgick till 0,23 (-0,07) kr [...]
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
29/11/2018
I-Mab’s Broad and Innovative Pipeline to Leverage TRACON’s U.S. Product Development Solution Platform SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical [...]
Rule 2.9 Announcement
29/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 29 November 2018 [...]
Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®
29/11/2018
Oasmia Pharmaceutical AB (Nasdaq: OASM) today announce that the company has signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology and know-how are [...]
AbbVie sponsored REACH study for the use of Genedrive HCV assay in pharmacies
29/11/2018
For release: 29 November genedrive plc ("genedrive" or the "Company") AbbVie sponsored REACH study for the use of Genedrive HCV assay in pharmacies genedrive plc (AIM: GDR), the near patient molecular diagnostics [...]
ObsEva SA to Host R&D Investor Day December 7, 2018
29/11/2018
Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for serious [...]
Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.
29/11/2018
This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn's, Bronchopulmonary dysplasia, Epilepsy and Stroke Amsterdam, The Netherlands - 29 [...]
Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
29/11/2018
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free at two years[1] Young [...]
Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results
29/11/2018
PRESS RELEASE: 29 November 2018, 07:00 CET Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results Mechelen, Belgium, 29 November 2018 - Biocartis Group NV (the 'Company' or ' [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
29/11/2018
Regulated information Gosselies, Belgium, 29 November 2018, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
29/11/2018
Information réglementée Gosselies, Belgique, le 29 novembre 2018, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins [...]
Revive Therapeutics Announces Results for the Three Months Ended September 30, 2018
29/11/2018
TORONTO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (“Revive” or the “Company”) , a specialty cannabis company focused on the research, development and [...]
L’autotest de dépistage du VIH INSTI obtient le statut de préqualification de l’OMS pour le test à domicile
29/11/2018
L’autotest de dépistage du VIH INSTI qui a récemment obtenu la préqualification de l’OMS impose sa marque alors qu’il s’étend à de nouveaux marchés VANCOUVER, Colombie-Britannique, 29 nov. 2018 (GLOBE NEWSWIRE) -- [...]
aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
29/11/2018
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
29/11/2018
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve [...]

Pages